Royce & Associates LP Sells 107,638 Shares of Elanco Animal Health Incorporated $ELAN

Key Points

• Royce & Associates LP cut its Elanco Animal Health stake by 17.9% in the fourth quarter, selling 107,638 shares and leaving it with 494,926 shares worth about $11.2 million.
• Several insiders bought shares in mid-May, including CEO Jeffrey N. Simmons and insider Rajeev A. Modi, signaling recent confidence from management.
• Analysts remain generally positive on ELAN, with a consensus Moderate Buy rating and an average price target of $28.20; the company also beat earnings and revenue estimates in its latest quarterly report.

Royce & Associates LP lessened its position in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 17.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 494,926 shares of the company's stock after selling 107,638 shares during the period. Royce & Associates LP owned about 0.10% of Elanco Animal Health worth $11,200,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Huntington National Bank increased its holdings in Elanco Animal Health by 136.7% during the 3rd quarter. Huntington National Bank now owns 1,882 shares of the company's stock worth $38,000 after purchasing an additional 1,087 shares in the last quarter. Whittier Trust Co. of Nevada Inc. increased its holdings in Elanco Animal Health by 80.3% during the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 2,021 shares of the company's stock worth $42,000 after purchasing an additional 900 shares in the last quarter. Torren Management LLC bought a new position in Elanco Animal Health during the 4th quarter worth about $46,000. Fifth Third Bancorp increased its holdings in Elanco Animal Health by 3,018.3% during the 3rd quarter. Fifth Third Bancorp now owns 2,900 shares of the company's stock worth $58,000 after purchasing an additional 2,807 shares in the last quarter. Finally, Farther Finance Advisors LLC increased its holdings in Elanco Animal Health by 43.6% during the 4th quarter. Farther Finance Advisors LLC now owns 3,089 shares of the company's stock worth $70,000 after purchasing an additional 938 shares in the last quarter. Institutional investors own 97.48% of the company's stock.

Insider Activity

In other news, CEO Jeffrey N. Simmons bought 4,971 shares of the business's stock in a transaction that occurred on Friday, May 15th. The stock was acquired at an average cost of $20.09 per share, for a total transaction of $99,867.39. Following the purchase, the chief executive officer owned 171,971 shares of the company's stock, valued at approximately $3,454,897.39. This trade represents a 2.98% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Rajeev A. Modi bought 4,911 shares of the business's stock in a transaction that occurred on Friday, May 15th. The stock was purchased at an average price of $20.35 per share, with a total value of $99,938.85. Following the completion of the purchase, the insider directly owned 160,812 shares in the company, valued at $3,272,524.20. The trade was a 3.15% increase in their position. The disclosure for this purchase is available in the SEC filing. Company insiders own 1.14% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on ELAN. UBS Group reiterated a "buy" rating on shares of Elanco Animal Health in a report on Tuesday, March 10th. Citigroup raised their price objective on Elanco Animal Health from $30.00 to $31.00 and gave the company a "buy" rating in a report on Thursday, May 7th. Leerink Partners raised their price objective on Elanco Animal Health from $26.00 to $30.00 and gave the company an "outperform" rating in a report on Tuesday, February 24th. JPMorgan Chase & Co. raised their price objective on Elanco Animal Health from $28.00 to $30.00 and gave the company an "overweight" rating in a report on Thursday, May 7th. Finally, Wall Street Zen cut Elanco Animal Health from a "strong-buy" rating to a "buy" rating in a report on Sunday. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $28.20.

Elanco Animal Health Price Performance

Shares of NYSE ELAN opened at $23.71 on Thursday. The stock has a market capitalization of $11.84 billion, a price-to-earnings ratio of -47.41, a PEG ratio of 2.46 and a beta of 1.69. The business has a 50-day moving average of $23.00 and a 200-day moving average of $23.30. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.16 and a quick ratio of 1.12. Elanco Animal Health Incorporated has a fifty-two week low of $12.97 and a fifty-two week high of $27.72.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last announced its quarterly earnings data on Wednesday, May 6th. The company reported $0.40 earnings per share for the quarter, beating the consensus estimate of $0.34 by $0.06. The company had revenue of $1.37 billion during the quarter, compared to analysts' expectations of $1.28 billion. Elanco Animal Health had a positive return on equity of 7.42% and a negative net margin of 4.95%.Elanco Animal Health's revenue for the quarter was up 14.9% compared to the same quarter last year. During the same quarter last year, the company earned $0.37 EPS. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. As a group, sell-side analysts predict that Elanco Animal Health Incorporated will post 1.11 earnings per share for the current fiscal year.

Elanco Animal Health Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco's portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.